330 related articles for article (PubMed ID: 21060032)
21. TP53 Mutation, MYCN Amplification, and Large Cell/Anaplastic Histology in Medulloblastoma.
Das A; Zameer L; Vinarkar S; Singh M; Parihar M; Arora N; Chandra A; Achari RB
Indian J Pediatr; 2018 Aug; 85(8):684-685. PubMed ID: 29139064
[No Abstract] [Full Text] [Related]
22. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
23. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
24. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.
Goschzik T; Mynarek M; Doerner E; Schenk A; Spier I; Warmuth-Metz M; Bison B; Obrecht D; Struve N; Kortmann RD; Schmid M; Aretz S; Rutkowski S; Pietsch T
Acta Neuropathol; 2022 Dec; 144(6):1143-1156. PubMed ID: 36181537
[TBL] [Abstract][Full Text] [Related]
26. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
27. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.
Pietsch T; Schmidt R; Remke M; Korshunov A; Hovestadt V; Jones DT; Felsberg J; Kaulich K; Goschzik T; Kool M; Northcott PA; von Hoff K; von Bueren AO; Friedrich C; Mynarek M; Skladny H; Fleischhack G; Taylor MD; Cremer F; Lichter P; Faldum A; Reifenberger G; Rutkowski S; Pfister SM
Acta Neuropathol; 2014 Jul; 128(1):137-49. PubMed ID: 24791927
[TBL] [Abstract][Full Text] [Related]
29. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
[TBL] [Abstract][Full Text] [Related]
30. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
31. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
Bourdeaut F; Grison C; Maurage CA; Laquerriere A; Vasiljevic A; Delisle MB; Michalak S; Figarella-Branger D; Doz F; Richer W; Pierron G; Miquel C; Delattre O; Couturier J
Cancer Genet; 2013 Apr; 206(4):124-9. PubMed ID: 23578955
[TBL] [Abstract][Full Text] [Related]
32. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome.
Rieber J; Remke M; Hartmann C; Korshunov A; Burkhardt B; Sturm D; Mechtersheimer G; Wittmann A; Greil J; Blattmann C; Witt O; Behnisch W; Halatsch ME; Orakcioglu B; von Deimling A; Lichter P; Kulozik A; Pfister S
Genes Chromosomes Cancer; 2009 Jul; 48(7):558-68. PubMed ID: 19378321
[TBL] [Abstract][Full Text] [Related]
33. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
Fattet S; Haberler C; Legoix P; Varlet P; Lellouch-Tubiana A; Lair S; Manie E; Raquin MA; Bours D; Carpentier S; Barillot E; Grill J; Doz F; Puget S; Janoueix-Lerosey I; Delattre O
J Pathol; 2009 May; 218(1):86-94. PubMed ID: 19197950
[TBL] [Abstract][Full Text] [Related]
34. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
35. Clinical Aggressiveness of TP53-Wild Type Sonic Hedgehog Medulloblastoma With MYCN Amplification, Chromosome 17p Loss, and Chromothripsis.
Mitani Y; Fukuoka K; Mori M; Arakawa Y; Matsushita Y; Hibiya Y; Honda S; Kobayashi M; Tanami Y; Kanemura Y; Ichimura K; Nakazawa A; Kurihara J; Koh K
J Neuropathol Exp Neurol; 2021 Jan; 80(2):205-207. PubMed ID: 33367701
[No Abstract] [Full Text] [Related]
36. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
37. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
[TBL] [Abstract][Full Text] [Related]
38. Overexpressed TP73 induces apoptosis in medulloblastoma.
Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
[TBL] [Abstract][Full Text] [Related]
39. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implications of chromosome 17p deletions in human medulloblastomas.
Batra SK; McLendon RE; Koo JS; Castelino-Prabhu S; Fuchs HE; Krischer JP; Friedman HS; Bigner DD; Bigner SH
J Neurooncol; 1995; 24(1):39-45. PubMed ID: 8523074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
